MedPath

Phase I/II trial of nab-Paclitaxel,Carboplatin,plus Bevacizumab chemotherapy for patients with advanced Non-Squamous Non-Small Cell Lung Cancer.

Phase 1
Conditions
Advanced Non-Squamous Non-Small Cell Lung Cancer
Registration Number
JPRN-UMIN000013201
Lead Sponsor
Cancer Institute Hospital of JFCR
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
61
Inclusion Criteria

Not provided

Exclusion Criteria

The patients who have brain metastasis and have symptom or need therapy. The patients who have hemoptysis.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PhaseI:Dose Limiting Toxicity(DLT),Minimal Tolerated Dose(MTD),Recommended Dose(RD) PhaseII:Objective Response Rate(ORR)
Secondary Outcome Measures
NameTimeMethod
PhaseI:Safety,Objective Response Rate(ORR),Progression Free Survival(PFS),Overall Survival(OS)
© Copyright 2025. All Rights Reserved by MedPath